Antibiotics and Resistance: Are New Molecules in the Pipeline? Researchers in Tours Explore New Antibacterial Strategies

ntibiotic resistance is one of the major challenges facing modern medicine. As bacterial pathogens increasingly develop resistance to existing treatments, the search for new antibacterial molecules has become an essential part of antimicrobial research. However, discovering a promising compound is only the first step: understanding its mechanism of action, assessing its toxicity and determining whether it can be developed into an effective treatment require years of multidisciplinary investigation.

At the University of Tours, France, researchers from two complementary laboratories are working on precisely these questions. Their research combines organic chemistry and bacteriology to investigate new antibacterial compounds inspired by natural molecules. On Thursday, November 19, 2026, Dr. Émilie Camiade and Dr. Julien Pétrignet will present their work during a new MédiSciences conference entitled “Antibiotics and Resistance: Are New Molecules in the Pipeline?”

You can attend the conference in person or online. The conference will be delivered in French.

JOIN THE CONFERENCE ONLINE — IN FRENCH

Thursday, November 19, 2026 | 6:00–7:30 PM (Paris time)

REGISTER AND ACCESS THE MICROSOFT TEAMS CONFERENCE

Free registration is required to attend online.

In-person attendance is also possible at the Faculty of Medicine, Tonnellé site, Conference Room 2, University of Tours.

The conference is organised as part of the MédiSciences programme, which aims to introduce students and the wider public to research in human health.

Émilie Camiade is a lecturer and researcher in bacteriology at the University of Tours and deputy head of the Bacteria and Maternal-Foetal Risk research team (BRMF), part of the UMR 1282 Infectiology and Public Health unit associated with INRAE. Her research explores bacterial adaptation to environmental conditions, particularly the role of carbon metabolism in the physiology of Streptococcus agalactiae, also known as Group B Streptococcus. This bacterium can be carried asymptomatically but is also responsible for severe infections, particularly in newborns.

Alongside this fundamental research, Camiade has been involved in the development and characterisation of new antibacterial molecules and therapeutic strategies. Since 2018, she has collaborated with chemists from the University of Tours' SIMBA laboratory on the antibacterial properties of chemically modified natural phthalides. She is also involved in a separate research direction devoted to the development and formulation of biopharmaceutical products in green solvents to help prevent infections caused by S. agalactiae.

Julien Pétrignet is a researcher at the SIMBA laboratory (Synthesis and Isolation of Bioactive Molecules), where his work focuses on organic synthesis methodologies and medicinal chemistry. His expertise includes the development of new synthetic routes and the preparation of structurally diverse molecules with potential biological activities. In the collaboration with Camiade's team, this chemical expertise is combined with microbiological testing to investigate the antibacterial properties of newly synthesised compounds.

One of the main research directions connecting the two laboratories concerns phthalides, a family of chemical structures found in natural products. A particularly interesting starting point is cytosporone E, a secondary metabolite isolated from an endophytic fungus that has demonstrated antibacterial activity. Rather than relying exclusively on the naturally occurring compound, the researchers have explored pharmacomodulation: modifying its chemical structure to investigate whether new derivatives can display improved biological properties.

The aim is to obtain compounds with stronger antibacterial activity, while also addressing limitations such as toxicity and restricted activity against different bacterial groups. This requires close interaction between chemistry and microbiology. New derivatives must first be synthesised and characterised, then evaluated against bacterial strains to determine their minimum inhibitory concentrations and their effects on bacterial physiology.

The collaboration has already produced several peer-reviewed publications. In January 2024, Enzo Eddebbarh, Léa Moutardier, Jérôme Thibonnet, Émilie Camiade and Julien Pétrignet published “Direct Synthesis of 3-Arylphthalides Promoted by Eaton's Reagent” in the European Journal of Organic Chemistry. The study described a direct synthetic approach to 3-arylphthalides using Eaton's reagent under metal- and solvent-free reaction conditions. Selected compounds were subsequently evaluated against methicillin-resistant Staphylococcus aureus (MRSA).

The antibacterial experiments showed that certain derivatives displayed promising in-vitro activity. Three selected compounds had minimum inhibitory concentrations ranging from 8.0 to 14.3 µM against the tested MRSA strain, compared with 22.3 µM for cytosporone E. These results demonstrate that chemical modification can substantially influence antibacterial activity. However, they represent laboratory measurements against a specific bacterial strain and do not establish therapeutic efficacy in patients.

A second publication appeared in Advanced Synthesis & Catalysis in September 2025. “A Versatile Route to 3,3-Disubstituted Phthalides Via Arylogous Michael Addition Catalyzed by Organic Base”, authored by Enzo Eddebbarh, Lou Mazoyer, Jérôme Thibonnet and Julien Pétrignet, presented a complementary synthetic methodology. The researchers developed an organocatalytic approach to combine 3-arylphthalides with Michael acceptors, allowing access to a broader range of 3,3-disubstituted structures under relatively mild conditions. The method also demonstrated functional-group tolerance and gram-scale feasibility. Importantly, this second paper concerns synthetic methodology; it should not be interpreted as a demonstration of antibacterial activity for every newly prepared compound.

The microbiological characterisation of these molecules has also progressed. At the 2025 MICROBES congress of the French Society for Microbiology, held in Bordeaux from September 24 to 26, Léa Moutardier presented a selected short oral communication entitled “Identification of the bacterial target of phthalides with antibacterial activity and characterization of associated phenotypes”. The work involved researchers from both SIMBA and BRMF, including Enzo Eddebbarh, Julien Pétrignet and Émilie Camiade.

The presentation described several biological effects observed with selected phthalide derivatives. At sub-inhibitory concentrations, some compounds induced defects in bacterial cell separation, suggesting interference with processes involved in bacterial division or cell-envelope organisation. The molecules also displayed a relatively narrow antibacterial spectrum, with activity mainly observed against the Gram-positive bacteria tested.

Another interesting observation concerned biofilm formation. Some derivatives, at concentrations corresponding to 0.2 times their minimum inhibitory concentration, inhibited biofilm formation by approximately 80%. The researchers also reported synergistic effects when certain compounds were combined with beta-lactam antibiotics. These findings suggest that the molecules could potentially be investigated as complementary agents alongside conventional antibiotics, although the observations remain preclinical.

The researchers also evaluated cytotoxicity using primary human fibroblasts and keratinocytes in vitro, as well as the Galleria mellonella model in vivo. Moderate cytotoxicity was observed in the human cell cultures, whereas no cytotoxicity was detected in the insect model under the tested conditions. These preliminary findings are useful for assessing the development potential of the compounds, but they do not establish safety in humans or in mammalian infection models.

An additional presentation at the 37th Biotechnocentre Colloquium, held in Orléans on October 16–17, 2025, provided further information about the investigation of the molecular target. The poster, entitled “Discovery of a new line of defence: characterisation of a new family of antibiotics”, described the use of Thermal Proteome Profiling (TPP), a proteomics-based approach that can help identify proteins whose thermal stability changes in the presence of a compound.

The first results highlighted three proteins showing significant changes in thermal stability following exposure to the phthalide. However, these proteins were found exclusively in S. aureus, whereas the researchers' observations suggested that the relevant bacterial target should also be present in Gram-negative bacteria. Consequently, these proteins could not yet be considered the definitive molecular target. Identifying and experimentally validating the precise target remains an important challenge for understanding how these molecules exert their antibacterial effects.

The work has also generated doctoral research. Enzo Eddebbarh, listed by SIMBA as a doctoral researcher supervised by Julien Pétrignet, defended a thesis in December 2025 on the development of new synthetic methodologies to access bio-inspired phthalides with antibacterial activity. The thesis formed part of the wider collaboration between chemistry and bacteriology, and was followed by further publications and research presentations. The MICROBES and Biotechnocentre contributions therefore represent documented stages in the continuing characterisation of these compounds, rather than the first presentation of an entirely new research programme.

Taken together, these studies illustrate the different stages involved in developing new antibacterial candidates. The chemical structures must be synthesised and optimised, their activity must be tested against relevant bacterial strains, and their effects on bacterial physiology must be investigated. Researchers must also determine the molecular target, assess possible toxicity and establish whether the compounds offer advantages over existing treatments.

Despite the encouraging observations, the phthalide derivatives investigated in Tours should currently be considered experimental antibacterial candidates, not antibiotics ready for clinical use. Their relatively narrow spectrum, unresolved molecular target and preliminary toxicity data highlight the substantial work that remains before any therapeutic application could be considered. Further studies will be necessary to establish their selectivity, pharmacological properties and efficacy in relevant infection models.

The MédiSciences conference on November 19 offers an opportunity to hear directly from the researchers involved in this work and to discover how medicinal chemistry and bacteriology can be combined in the search for new antibacterial strategies. It may also provide an update on the progress made since the publications and scientific presentations of 2024 and 2025, particularly regarding the identification of the molecular target and the future development of these compounds.

For students, researchers and anyone interested in antimicrobial resistance, this conference is an opportunity to discover ongoing research at the University of Tours and the challenges involved in translating promising laboratory findings into potential therapeutic applications.

Register here to attend online:
https://events.teams.microsoft.com/event/4f1a7024-3c09-4c8b-a2de-0da12d53fa02@16150599-ebb0-4fcf-94a5-6010823c7bd5?source=copyLinkLegacyShareLinkDialog





References :

University of Tours. “MédiSciences – E. Camiade & J. Pétrignet: Antibiotiques et résistance : de nouvelles molécules dans les tuyaux ?” November 19, 2026.
https://medisciences.univ-tours.fr/medisciences-e-camiade-j-petrignet-antibiotiques-et-resistance-de-nouvelles-molecules-dans-les-tuyaux

University of Tours. Émilie Camiade – Research profile.
https://www.univ-tours.fr/annuaire/emilie-camiade

Infectiology and Public Health, INRAE / University of Tours. “Bacteria and Maternal-Foetal Risk – Research themes.”
https://infectiologie-santepublique.val-de-loire.hub.inrae.fr/recherches/pole-bacteriologie/bacteries-et-risque-materno-foetal

SIMBA, University of Tours. “Evaluation of the antibacterial activities of natural phthalide analogues.”
https://simba.univ-tours.fr/la-recherche/axe-fondamental/chimie-des-substances-naturelles

Eddebbarh, E. et al. (2024). “Direct Synthesis of 3-Arylphthalides Promoted by Eaton's Reagent.” European Journal of Organic Chemistry.
https://doi.org/10.1002/ejoc.202301303

Eddebbarh, E. et al. (2025). “A Versatile Route to 3,3-Disubstituted Phthalides Via Arylogous Michael Addition Catalyzed by Organic Base.” Advanced Synthesis & Catalysis.
https://doi.org/10.1002/adsc.70128

Moutardier, L. et al. (2025). “Identification of the bacterial target of phthalides with antibacterial activity and characterization of associated phenotypes.” MICROBES 2025, 20th National Congress of the French Society for Microbiology, September 24–26, 2025.

SIMBA, University of Tours. “Natural Deep Eutectic Solvents for Sustainable Development.”
https://simba.univ-tours.fr/la-recherche/axe-applique

Comments

Most Consulted Articles

Bacteriophages Disarm Inflammation-Associated E. coli Without Erasing the Gut Microbiome in IBD

🌐 PhageAtLabs® — a global interactive mapping of academic laboratories in phage research.

History Part 12 : Post-War Stagnation and Phage Therapy’s Marginalization in the West (1945–1980s)

The Phage Therapy in the spotlight !

Phagos Launches CAPHARD, a 900-Million-Parameter AI Model to Predict Phage–Bacteria Interactions